Christoph Max Krell

Title: Christoph Max Krell: Innovator in Pharmaceutical Chemistry

Introduction

Christoph Max Krell is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of MEK inhibitors. With a total of 12 patents to his name, Krell's work has had a substantial impact on drug formulation and preparation.

Latest Patents

Krell's latest patents focus on the preparation of and formulation comprising a MEK inhibitor. His inventions include processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide. He has also developed methods for preparing crystallized versions of this compound, along with intermediates that are useful in these processes. Additionally, pharmaceutical compositions that include this crystallized compound are part of his innovative work.

Career Highlights

Throughout his career, Krell has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Novartis AG and Array Biopharma Inc. His experience in these organizations has allowed him to refine his expertise in drug development and formulation.

Collaborations

Krell has collaborated with several professionals in his field, including Marian Misun and Daniel Andreas Niederer. These collaborations have contributed to the advancement of his research and innovations.

Conclusion

Christoph Max Krell is a distinguished inventor whose work in pharmaceutical chemistry continues to influence the industry. His innovative patents and collaborations highlight his commitment to advancing drug formulation and preparation.